This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Nov;7(11):611.

doi: 10.1038/nrclinonc.2010.161.

Targeted therapies: New standard of therapy for HER2-positive gastric cancers?

PMID: 21049571
DOI: 10.1038/nrclinonc.2010.161

Comment

Targeted therapies: New standard of therapy for HER2-positive gastric cancers?

Rebecca Kirk. Nat Rev Clin Oncol. 2010 Nov.

. 2010 Nov;7(11):611.

doi: 10.1038/nrclinonc.2010.161.

Author

PMID: 21049571
DOI: 10.1038/nrclinonc.2010.161

No abstract available

PubMed Disclaimer

Comment on

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Bang YJ, et al. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.

References

1. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal